MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by PETERSON, M. J.
Right arrow Articles by ASHMORE, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PETERSON, M. J.
Right arrow Articles by ASHMORE, J.

Molecular Pharmacology, Vol 4, 1-9, Copyright © 1968 by the American Society for Pharmacology and Experimental Therapeutics

Nicotinic Acid: Studies on the Mechanism of Its Antilipolytic Action

M. J. PETERSON 1, C. C. HILLMAN 1, and J. ASHMORE 1

1 Department of Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana 46207

Nicotinic acid in vitro is known to depress basal lipolytic rates in adipose tissue and also to inhibit the action of a number of agents which stimulate adipose tissue lipolysis. Three possible mechanisms by which nicotinic acid could exert this antilipolytic effect have been examined. The rat epididymal fat pad was used as an adipose tissue source. In vitro nicotinic acid was found to have no effect on fat pad phosphodiesterase activity. Similarly, no direct effect of this drug on lipase activity could be demonstrated. Nicotinic acid in vitro was observed to inhibit, by about 50%, the increased lipolytic rates induced in isolated fat pad sections with theophylline. This inhibitory action, however, was antagonized by the further in vitro addition of the beta-adrenergic blocking agent, nethalide, (pronethalol). Also, this antagonism appeared to be a direct one. It is suggested from these results that nicotinic acid does not exert its antilipolytic action by either increasing the degradation of cyclic 3',5'-AMP or by inhibiting directly the activity of lipase. It would appear, however, that nicotinic acid acts at a site that is either identical with the receptor for nethalide or is closely associated to it. Thus, it seems possible that nicotinic acid may exert its antilipolytic action by depressing the production of cyclic 3',5'-AMP.

Note:
ACKNOWLEDGMENT These studies were supported in paid by Public Health Service grants AM 07211 and GM 953.

Submitted on July 7, 1967




This article has been cited by other articles:


Home page
 ScienceHome page
D. McMahon
Chemical Messengers in Development: A Hypothesis
Science, September 20, 1974; 185(4156): 1012 - 1021.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1968 by the American Society for Pharmacology and Experimental Therapeutics